Bionano Genomics, Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $7.37 million, a 21% increase from $6.07 million in the same period last year. The growth was primarily driven by a 15% rise in product revenue, which reached $6.93 million, compared to $6.02 million in Q3 2024. Service and other revenue saw a significant increase, rising to $433,000 from just $52,000 a year earlier. Despite this revenue growth, the company reported a net loss of $8.5 million for the quarter, a substantial improvement from the $44.2 million loss recorded in Q3 2024.
In terms of operational efficiency, Bionano Genomics has made notable strides. The cost of revenue decreased dramatically by 72% to $3.99 million, down from $14.52 million in the prior year, largely due to the absence of significant write-offs related to obsolete inventory that impacted the previous year's figures. Total operating expenses also fell sharply, decreasing by 66% to $11.91 million, compared to $35.46 million in Q3 2024. This reduction was attributed to the company's restructuring efforts, which included workforce reductions and a strategic shift in focus towards maximizing the utilization of existing optical genome mapping (OGM) systems.
The company’s installed base of OGM systems grew to 384 as of September 30, 2025, marking a 4% increase from 368 units a year prior. Additionally, Bionano sold 8,390 flowcells during the quarter, a 7% increase from the 7,835 sold in Q3 2024. However, the company anticipates that the pace of revenue growth may slow due to its strategic shift to focus on existing customers rather than new placements of OGM systems.
Bionano's financial position remains precarious, with cash and cash equivalents totaling $3.07 million as of September 30, 2025, down from $9.17 million at the end of 2024. The company also holds $18.5 million in short-term investments and $10.3 million in restricted investments. Management has expressed substantial doubt about the company's ability to continue as a going concern within the next 12 months unless additional capital is raised. The company is actively exploring options for financing, including public or private equity offerings, but acknowledges the uncertainty surrounding the availability and terms of such funding.
Looking ahead, Bionano Genomics plans to continue its focus on enhancing the adoption of its existing products while managing costs. The company expects to incur ongoing operating losses as it navigates its restructuring and seeks to stabilize its financial condition. The management's outlook emphasizes the need for additional capital to support operations and growth initiatives, underscoring the challenges the company faces in the current economic environment.
About Bionano Genomics, Inc.
Bionano Genomics, Inc. develops and markets optical genome mapping (OGM) systems, software, and nucleic acid purification solutions for comprehensive structural variation (SV) analysis in genomics. Its core products include the Saphyr® and Stratys™ OGM systems, VIA™ software for integrated genomic data interpretation, and the Ionic® Purification system. Serving researchers, clinicians, and biopharmaceutical companies, Bionano’s platform offers a scalable, cost-effective alternative to traditional cytogenetics and sequencing for genetic disease, cancer, and cell therapy applications.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.